Link between Angiotensin II and TGF-β in the Kidney
Mineral and Electrolyte Metabolism · 1998
DOI: 10.1159/000057367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mineral and Electrolyte Metabolism, 1998. Verfasst von G Wolf. Beteiligte Einrichtung: Department of Medicine, University of Hamburg, Germany. wolf@uke.uni-hamburg.de. Hauptthemen laut MEDLINE: Kidney Failure, Chronic. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Glomerulosclerosis and tubulointerstitial fibrosis are common morphological correlates of many end-stage kidneys. There is ample evidence that transforming growth factor-β (TGF-β) plays a major role in these alterations by directly stimulating synthesis of many extracellular matrix components and reducing collagenase production, finally leading to renal scarring. Although many factors may induce TGF-β expression in the kidney, one very interesting aspect is the link between angiotensin II (ANG II) and TGF-β. Originating from observations in vascular smooth muscle cells, there are now several additional studies showing that ANG II stimulates TGF-β expression in the kidney. Although cell culture studies have convincingly demonstrated that the vasoactive peptide directly stimulates transcription as well as bioactivation of TGF-β, the in vivo evidence is more indirect. Nevertheless, there are several pathophysiological situations including unilateral ureteral obstruction, chronic cyclosporin A nephrotoxicity, various models of hypertension, and probably diabetic nephropathy in which ANG II-mediated TGF-β induction has been demonstrated to play an important role in the progression of the disease. The fascinating aspect of this relationship between ANG II and TGF-β is the fact that hemodynamic changes as well as structural changes are linked together generating a unifying model of progression of chronic renal failure with ANG II as the key player. Angiotensin-converting enzyme (ACE) inhibitor and the more recently introduced AT1-receptor blocker may be potential drugs to interfere with this ANG II-mediated TGF-β expression. Therefore, these drugs should not only be considered as antihypertensive medications, but should rather be viewed as renoprotective substances influencing renal remodeling by preventing local TGF-β expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Hamburg, Germany. wolf@uke.uni-hamburg.de
Zitieren
APA
Wolf, G. (1998). Link between Angiotensin II and TGF-β in the Kidney. Mineral and Electrolyte Metabolism. https://doi.org/10.1159/000057367
Vancouver
Wolf G. Link between Angiotensin II and TGF-β in the Kidney. Mineral and Electrolyte Metabolism. 1998. doi:10.1159/000057367
BibTeX
@article{Wolf1998,
author = {Wolf, G},
title = {Link between Angiotensin II and TGF-β in the Kidney},
journal = {Mineral and Electrolyte Metabolism},
year = {1998},
doi = {10.1159/000057367}
}
EUVIMED